Table 6.
COVID-19 outcomes in 25OHD-sufficient, cholecalciferol-supplemented patients compared to unsupplemented, 25OHD-deficient patients
| Cholecalciferol treated and serum 25OHD ≥ 30 ng/ml (n = 9474) | Untreated controls with serum 25OHD < 20 ng/ml (n = 7616) | Univariate analysis3 | Multivariate analysis4 | |||
|---|---|---|---|---|---|---|
| HR (CI 95%) | p | HR (CI 95%) | p | |||
| SARS-CoV2 infection1, n (%) | 309 (3.3%) | 430 (5.6%) | 0.57 (0.50–0.66) | < 0.001 | 0.66 (0.57–0.77) | < 0.001 |
| Severe COVID-192, n (%) | 65 (0.7%) | 99 (1.3%) | 0.53 (0.39–0.72) | < 0.001 | 0.72 (0.52–1.00) | 0.050 |
| COVID-19 mortality, n (%) | 56 (0.6%) | 96 (1.3%) | 0.47 (0.34–0.65) | < 0.001 | 0.66 (0.46–0.93) | 0.018 |
25OHD 25-hydroxyvitamin D
1Positive PCR or clinical diagnosis of SARS-CoV2 infection
2Composite outcome of need for non-invasive mechanical ventilation, orotracheal intubation, mechanical ventilation, intensive care unit admission or death
3Unadjusted Cox regression analysis
4Cox regression analysis controlling for all covariates